GlassScriptPhysician profile
Aarti Bhasin
NPI 1336515147
$6,616.73
in general payments reported to CMS, 2019-2025
31 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $147 · 2021: $652 · 2022: $1,142 · 2023: $1,424 · 2024: $2,076 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $791.78 | 2021-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $696.61 | 2023-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $572.64 | 2020-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $547.65 | 2021-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $427.24 | 2022-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $411.47 | 2020-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $343.28 | 2019-2024 | Ultomiris |
| Amgen INC. | $337.17 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $324.28 | 2020-2025 | Rayaldee |
| Travere Therapeutics, INC. | $272.59 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.89 | 2022-2024 | |
| Scpharmaceuticals INC. | $187.75 | 2024-2025 | |
| Lilly USA, LLC | $157.14 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $155.88 | 2021-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $154.33 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $125.00 | 2024 | |
| Ardelyx, INC. | $112.15 | 2023-2024 | Ibsrela |
| Edwards Lifesciences Corporation | $96.47 | 2025 | Sapien 3 Ultra Resilia |
| Fresenius USA Marketing, INC. | $92.81 | 2021-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.10 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $81.67 | 2021-2024 | Lupkynis |
| Abbvie INC. | $68.17 | 2025 | |
| Pfizer INC. | $65.68 | 2025 | |
| Akebia Therapeutics INC | $52.35 | 2021-2025 | Vafseo |
| Daiichi Sankyo INC. | $47.77 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.14 | 2020-2023 | Gattex |
| Renalytix Ai, INC. | $36.85 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $22.23 | 2023 | Benlysta |
| Cumberland Pharmaceuticals, INC. | $17.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarti Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.